The W.S. Badger Company, Inc.

Warning LetterOpen

United StatesFEI 3009946959Issued Apr 12, 2022Division of Pharmaceutical Quality Operations I

View Letter

Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3009946959.

Violations0

Issue DateApr 12, 2022

Product TypeDrugs

StatusOpen

Letter Details

Firm: The W.S. Badger Company, Inc.
Location: United States
FEI Number: 3009946959
Country: United States
Issue Date: April 12, 2022
Issuing Office: Division of Pharmaceutical Quality Operations I
Product Type: Drugs
Status: Open

Summary

The W.S. Badger Company, Inc. received a warning letter from the FDA's Division of Pharmaceutical Quality Operations I on April 12, 2022, regarding adulteration issues in their finished pharmaceutical products. Based on the subject line, the violations appear to involve current Good Manufacturing Practice (CGMP) non-compliance related to the manufacturing and quality control of finished drugs. While the specific details of the violations are not available from this metadata alone, the warning indicates that the company's pharmaceutical manufacturing operations did not meet FDA's required quality and safety standards.

The W.S. Badger Company, Inc. FDA Warning Letter, April 12, 2022